Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder CancerHugh Mostafid, Ashish M. Kamat, Marko Babjuk et al.|European Urology|2020Cited by 46
Biological characterization of cisplatin-resistant bladder cancer: Implications for second-line treatments?Roland Seiler, P. Black, Ewan A. Gibb et al.|European Urology Supplements|2018Cited by 0
PD52-02 FGFR3 MUTATIONS AND THEIR RELATION TO FGFR3 EXPRESSION AND CLINICAL OUTCOME IN A LARGE RADICAL CYSTECTOMY COHORT: IMPLICATIONS FOR ANTI-FGFR3 BLADDER CANCER TREATMENT?Bas van Rhijn, T.C.M. Zuiverloon, Laura S. Mertens et al.|The Journal of Urology|2019Cited by 0
PD57-04 PROGNOSTIC VALUE OF THE WHO 1973 AND 2004 CLASSIFICATION SYSTEMS FOR GRADE IN NON-MUSCLE-INVASIVE T1 BLADDER CANCERE. Fransen Van De Putte, Bas van Rhijn, Theodorus van der Kwast et al.|The Journal of Urology|2017Cited by 0
Abstract B23: <i>FGFR3</i> mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?Bas van Rhijn, Tahlita C.M. Zuiverloon, Wolfgang Otto et al.|Clinical Cancer Research|2020Cited by 0